Rhythm Pharmaceuticals (RYTM) Total Current Liabilities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Total Current Liabilities data on file, last reported at $103.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 7.71% year-over-year to $103.2 million in Q1 2026; TTM through Mar 2026 was $103.2 million, a 7.71% decrease from a year earlier, with the FY2025 full-year figure at $105.9 million, down 8.29% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $103.2 million, down from $105.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for RYTM reached as high as $129.5 million in Q2 2025 and fell as low as $33.1 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $72.9 million across 5 years, with a median of $54.7 million in 2024.
• On a YoY basis, Total Current Liabilities climbed as much as 180.56% in 2022 and fell as far as 8.33% in 2022.
• Year by year, Total Current Liabilities stood at $39.8 million in 2022, then jumped by 38.67% to $55.2 million in 2023, then jumped by 109.26% to $115.5 million in 2024, then slipped by 8.29% to $105.9 million in 2025, then fell by 2.59% to $103.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $103.2 million in Q1 2026, $105.9 million in Q4 2025, and $104.3 million in Q3 2025.